Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Clinical trial NCT07008638 · RECRUITING
Trial details
- NCT number
- NCT07008638
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-07
- Primary completion
- 2027-12-30
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.